Introduction
============

Hepatocyte growth factor (HGF) is a potent growth stimulator of mature epithelial cells that plays an important role in regeneration and repair after injuries ([@b9]). Natural HGF is a heterodimeric protein of 96--110 kDa that consists of one α chain (67 kDa) and one β chain (35 kDa; [@b4]). Mesenchymal cells produce HGF as a single-chain precursor ([@b1]), which is activated by the proteolytic function of HGF activator ([@b11]). The HGF receptor, proto-oncogene c-Met, is a transmembrane protein expressed on epithelial cells ([@b23]). In addition, at least two binding sites for HGF on rat liver cell surfaces have been identified: a high-affinity c-Met/HGF receptor and a heparan sulphate proteoglycan (HSPG) binding site ([@b6]).

Basement membranes support epithelial and endothelial cells, prevent the passage of proteins, and generate histologically distinct compartments in the body. These membranes contain three major components: collagen IV, laminin, and HSPG, all of which are localized to the basal lamina portion of basement membranes. HSPG is a sulphated glycoprotein that binds and facilitates the cytokine--receptor interaction ([@b24]) and the conversion of promitogen HGF to the two-chain form ([@b6]) High levels of HGF have been reported in blood during acute injuries such as infectious diseases ([@b16]). HGF is also produced and released locally in a paracrine fashion at the site of acute injury ([@b13], [@b15]).

Surface plasmon resonance (SPR) is an optical technique that can simultaneously determine the affinity of a protein for several ligands by using individual surfaces on the sensor chip ([@b5]; [@b19]). SPR enables rapid analyte detection in real time without any labelling of samples and can be used for concentration determination, kinetic studies, and epitope mapping. The sensor surface of the SPR apparatus consists of a carboxymethylated dextran matrix, which is a hydrogel that provides a solution-like environment for the biospecific interactions. The carboxyl groups in the dextran matrix enable the covalent coupling of ligands (proteins, receptors, DNA, etc.) to the surface. Upon testing several ligands that might bind HGF, we found at least four ligands that were important for distinguishing between different lots of rHGF or endogenous HGF ([@b18], [@b22]). This difference might have biological consequences such as in the healing of ulcers ([@b17]).

ELISA is a reliable, sensitive method for the detection of proteins in samples. Since 1998, we have determined the concentration of HGF indifferent recombinant batches or blood by using a commercial ELISA kit (R&D, Minneapolis, MN, USA), but we could not ascertain the epitope against which the monoclonal antibody in the kit was produced. However, we have obtained reproducible results with the HGF ELISA kit in several studies ([@b13], [@b15],[@b16]). Whilst studying different lots of rHGF by ELISA, we observed that the concentration of rHGF in reconstituted samples correlated with the expected concentration. However, we did not find differences between biologically active and inactive lots by ELISA ([@b18]). Thus, the commercial ELISA kit determined the total amount of HGF but provided no information about the quality or activity. In a recent study, we showed that patients with chronic ulcers had HGF with decreased activity compared to patients with acute ulcers ([@b18]). This observation led us to investigate the quality of HGF both endogenously and in exogenous lots in *in vivo* (Nayeri et al.2007) and *in vitro* contexts.

In the present work, we introduce an SPR-based method to evaluate the quality and biological activity of rHGF according to the relative binding response of the cytokine to a number of biologically relevant ligands. The results obtained by this method correlated with high sensitivity and specificity to the results of a biological assay in the CCL-53.1 cell line, which responded specifically to HGF ([@b22]). The predominant binding response in biologically active HGF was identified. We also show that systemic HGF in the blood of patients with chronic leg ulcers had decreased quality compared with that of healthy controls.

Materials and methods
=====================

Patients
--------

Venous blood was gathered from 16 patients with chronic leg ulcers (age range, 42--87 years; median age, 77 years; 4 men). Some of these patients were included in previous studies ([@b18], [@b20]). The plasma was separated and kept frozen at −70°C pending analysis.

Ulcer secretions
----------------

Ulcer secretions were obtained from 10 patients with chronic leg ulcers and from 5 patients with acute ulcers. This material was used in previous studies from our group ([@b18], [@b20]).

Healthy controls
----------------

Plasma was obtained from 20 people (age range, 34--83 years; median age, 55 years; 10 men) without any signs of infection and with no history of chronic leg ulcers and kept frozen.

Recombinant human hepatocyte growth factor
------------------------------------------

Recombinant hHGF was a gift from Professor Nakamura, Osaka, Japan (2002). HGF was also obtained commercially (10 lots from R&D Systems, expressed in *Sf* 21 insect cells and in mouse myeloma cell line NSO; 3 lots from Sigma Aldrich, St Louis, MO, USA; 1 lot from Santa Cruz Inc., Santa Cruz, CA, USA; and 1 lot from GenWay Biotech Inc., San Diego, CA, USA).

Buffy coat
----------

A blood sample was obtained by venous puncture from a healthy blood donor, a 59-year-old man. The buffy coat was divided into two parts. The first portion was centrifuged at 3000*g* for 20 min, and the supernatant was collected. The other part was frozen at −70°C for 1h to haemolyse the blood cells, thawed, and centrifuged at 3000*g* for 20min, and the supernatant was collected. From the same individual, a blood sample was gathered in a tube (VENOJECT® silicone-coated) and centrifuged at 3000g for 20 min to collect the serum. Amounts (ELISA) and binding character (Biacore) of HGF in the buffy coat before and after haemolysis as well as in the serum were determined.

Endogenous HGF
--------------

Venous blood from a healthy 55-year-old man was gathered in sterile silicone-coated tubes (VENOJECT®) and placed at room temperature for 1h. The liquid on top of the coagulated blood was gathered and added to Kaighn\'s modification of Ham\'s F-12K medium (ATCC) supplemented with 10% foetal bovine serum (Sigma-Aldrich, Stockholm, Sweden) in an atmosphere of 5% CO~2~ and 95% air at 37°C. After 48 h, the medium was centrifuged at 3000g for 20 min, and the supernatant was collected and kept frozen at −70°C.

Evaluation of biological activity of HGF in a model of cell injury
------------------------------------------------------------------

The biological activity of HGF in samples was tested in an *in vitro* cell injury assay using transformed mouse skin epithelial cells (CCL-53.1 cell line). The method is described in a previous publication (Nayeri et al.2007). CCl-53.1 cells were grown in Kaighn\'s modification of Ham\'s F-12K medium (ATCC) supplemented with 15% horse serum and 2.5% foetal bovine serum (Sigma-Aldrich) in an atmosphere of 5% CO~2~ and 95% air at 37°C. After the cells reached confluence, they were separated with non-enzymatic cell dissociation solution (1 × )(Sigma-Aldrich), suspended in F-12K medium with 15% horse serum and 2.5% foetal bovine serum, and inoculated on a 24-well culture plate (Nunc Brand Products, Roskilde, Denmark). Cells were cultured under the same conditions for 24--48h until they reached confluence. Then, the confluent monolayer was scraped with a sterile steel device. Detached cells were washed with PBS, and fresh medium was added to the wells. The area of the square not covered by cells (mm^2^) was measured by microscopy (Olympus) and documented in each well. HGF was added, and the cells were incubated at 37°C in a humidified atmosphere containing 5% CO~2~. After 24 and 48h, the area not covered by a monolayer was measured again and documented.

Ligands
-------

Biologically relevant ligands of HGF \[monoclonal anti-HGF antibody(unknown epitope), polyclonal antibodies against different parts of HGF, and HGF receptors\] were obtained commercially ([Table I](#tbl1){ref-type="table"}) and immobilised on Biacore CM5 chips.

###### 

Ligands used to investigate the binding response of HGF by SPR.

  Immobilised ligands in SPR                    Source/product number    Code    Goal of investigation
  --------------------------------------------- ------------------------ ------- -----------------------------------------------------
  Monoclonal anti-HGF AB                        R&D Systems/RDS MAB294   MN      Determine amount of HGF
  Recombinant HGF receptor (c-met)/fc chimera   R&D Systems/358 MT       c-Met   Analyze HGF binding to c-met receptor
  HS proteoglycan                               Sigma-Aldrich/H4777      HSPG    Analyze HGF binding to HSPG
  Polyclonal anti-HGF AB, affinity isolated     Sigma-Aldrich/HH0652     PK      Determine amount of HGF
  H-170 rabbit polyclonal AB                    Santa Cruz/sc-13087      H-170   Bind amino acids 1--170 of human HGFβ
  N-19 affinity-purified goat polyclonal AB     Santa Cruz/sc-1356       N-19    Peptide mapping at the N-terminus of human HGFβ
  N-17 affinity-purified goat polyclonal AB     Santa Cruz/sc-1357       N-17    Peptide mapping at the N-terminus of human HGFα
  C-20 affinity-purified goat polyclonal AB     Santa Cruz/sc-1358       C-20    Peptide mapping at the C-terminus of human HGFα
  H-145 rabbit polyclonal AB                    Santa Cruz/sc-7949       H-145   Bind amino acids 32--176 of human HGFα
  D-19 goat polyclonal IgG                      Santa Cruz/sc-34461      D19     
                                                                                 Epitope mapping in an internal region of human HGFβ

All ligands were diluted (1:10 in 10 mM acetate buffer, pH 4.5) prior to immobilisation. AB, antibody.

SPR measurements and ligand immobilisation procedures
-----------------------------------------------------

SPR measurements were conducted at 760 nm in a fully automatic Biacore 2000 instrument (GE-Healthcare GmbH, Uppsala, Sweden) equipped with four flow cells. The flow cell temperature was 25°C in all experiments. The sample surfaces were carboxymethylated dextran CM5 chips (GE-Healthcare GmbH). Coupling of ligands to the carboxylic acid groups of the dextran hydrogel was carried out by conventional carbodiimide chemistry using 200 mM *N*-ethyl-*N*^′^-(3-diethylaminopropyl) carbodiimide (EDC) and 50 mM *N*-hydroxysuccinimide (NHS). The activation time was 7 min, followed by a 7-min ligand injection. Deactivation of the remaining active esters was performed by a 7-min injection of ethanolamine/hydrochloride at pH 8.5. A flow rate of 5 μl/min was used during immobilisation.

The ligands ([Table I](#tbl1){ref-type="table"}) were diluted in 10mM acetate buffer at a pH below the protein\'s isoelectric point, thus enhancing the electrostatic interactions between the dextran matrix and the ligands. The contact time was 7 min, which resulted in levels of immobilisation between 8000 and 30,000 response units (RU). After deactivation, the surfaces were washed with five subsequent 1-min injections of 5 mM glycine buffer, pH 2.0, with 1M NaCl (regeneration buffer). One of the flow cells was used to monitor the response due to interaction of HGF with the carboxymethylated dextran matrix. This flow cell was treated in the same way as the others during the immobilisation procedure, but the ligand immobilisation step was omitted.

Lyophilised rHGF was reconstituted and analysed at different concentrations. Sodium chloride (9 mg/ml, B. Braun Medical AB, Bromma, Sweden), distilled water(B. Braun Medical AB), phosphate buffer solution (pH 7.4, Apoteket AB, Umeå, Sweden), and HBS-EP (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3mM EDTA, 0.005% surfactant P20) (GE-Healthcare GmbH) were used as dilution buffers. A 1:1 mixture of 1M NaCl + 10 mM glycine, pH 2, was used as are generation buffer.

The blood samples were diluted 1:20 in phosphate buffer solution (pH 7.4, Apoteket AB). One injection of 1:1 1M NaCl:10 mM glycine, pH2, followed by one injection of borate 8.5 was used as a regeneration buffer for the blood samples. Leg ulcer secretions were diluted 1:10 in phosphate buffer solution. To avoid the effects of degrading enzymes, a protease inhibitor (1--5%) \[4-(2-aminoethyl) benzenesulphonyl fluoride (AEBSF), pepstatin A, E-64, bestatin, leupeptin, and aprotinin (but no metal chelators); Sigma Aldrich\] that specifically inhibited serine, cysteine, and aspartic proteases and aminopeptidases was added to the leg ulcer secretion 7--10 min prior to analysis. A1:1 mixture of 1M NaCl + 10 mM glycine, pH2, was used as a regeneration buffer.

The presented SPR data were extracted from the Biacore sensorgrams after the injections were finished, i.e. during the analyte dissociation phase. One Biacore RU corresponds to a surface concentration of 1 pg protein per mm^2^ ([@b26]). The binding of HGF to ligands was tested in fresh samples after reconstitution. The effect of time on the response was tested by continuous analysis of binding over time on the same chip and during the same run. The ligand binding of HGF after incubation at room temperature for 15 h was compared with ligand binding of a freeze-thawed sample. In addition, the effect of intracellular degrading enzymes on the binding of HGF to ligands was tested in buffy coat before and after haemolysis. A positive control was included at the beginning and at the end of each run to confirm the reliability of surfaces after several regeneration buffer injections.

ELISA
-----

A commercial ELISA kit (Quantikine Human HGF 96 tests, R&D Systems) was used to determine the concentration of HGF in samples. Our group has used this method since 1996, and the same person has performed all tests to reduce the inter- and intra-assay errors ([@b13], [@b15],[@b16]).

Statistics
----------

Parametric (ANOVA) as well as non-parametric (Mann--Whitney *U* test, Spearman\'s regression test) (Statistica) tests were used for statistical analyses, and *p* \> 0.05 was considered statistically significant.

Results and discussion
======================

The following procedures were repeated several times with different lots and had reproducible outcomes. Representative data are reported. The rHGF obtained as a gift from Professor Nakamura 2002 was biologically active and was SPR responsive (see below) and was used as positive control in some of the experiments. However in the reported results HGF produced by leukocytes in a healthy volunteer was used as a positive control.

rHGF
----

### Responsive lots

The rHGF lots that bound to all ligands ([Tables I](#tbl1){ref-type="table"} and [II](#tbl2){ref-type="table"}) with approximately the same absolute RU values (termed "SPR responsive") had a motogenic effect on CCL-53.1 cells in the *in vitro* model of cell injury (\>95% sensitivity and specificity). We showed previously ([@b22]) that the biologically active rHGF lots had motogenic effects on CCL-53.1 cells; therefore, the SPR responsive lots were considered biologically active ([Table II](#tbl2){ref-type="table"}). To simplify the calculation, we used the ratio of the binding responses to HSPG and to MN. Biological activity was observed in HGF lots in which the HSPG/MN ratio was ≥ 0.3. However, the cut-off ratio might be different in serum or plasma.

###### 

Analysis of SPR responsive rHGF

               MN (13065 RU)   HSPG (13092 RU)
  ------------ --------------- -----------------
  5 μg/ml      991             741
  2.5 μg/ml    644             421
  1.5 μg/ml    250             110
  0.6 μg/ml    150             49
  0.3 μg/ml    63              14.3
  0.1 μg/ml    25              4
  HBS buffer   −4              0

Freshly reconstituted rHGF was diluted to different concentrations in HBS buffer, and the binding signal to two ligands was reported by SPR. This lot of rHGF was biologically active on CCL-53.1 cells. There was a significant positive correlation between the HGF concentration (μg/ml) and the binding signal to MN (SPR) in this lot (*r* = 0.98%, *r*^2^ = 0.97%, *p* \< 0.0001). The immobilisation levels for ligands are given in parentheses.

In SPR responsive samples, there was a positive and significant correlation between HGF amount (μg/ml) and the SPR response to epitopes (*r*^2^ = 0.97, *p* \< 0.0001). As shown in [Table III](#tbl3){ref-type="table"}, the binding signals for monoclonal anti-HGF (MN) and polyclonal anti-HGF (PK) decreased with dilution of the rHGF sample. A similar finding was obtained when we analysed HGF in faeces from patients with acute infectious gastroenteritis ([@b19]). In those patients, the SPR signal response correlated significantly with the amount of HGF determined by ELISA (*r* = 72%, *p* \< 0.001). However, in another patient group with chronic inflammatory bowel disease, the SPR signal response did not correlate with ELISA results (article under preparation). These results might indicate that a positive correlation between ELISA and SPR is a determinant for biologically active HGF and that biologically active HGF is produced endogenously during acute inflammation.

###### 

SPR response (RU) and biological activity of samples containing HGF.

  Samples containing HGF            c--met (22113 RU)   MN (19194 RU)   HSPG (14899 RU)   PK (20978 RU)   Nude area in mm after 24 h (reported as ratio of + HGF area/control well area)
  --------------------------------- ------------------- --------------- ----------------- --------------- --------------------------------------------------------------------------------
  5 μg/ml GJ175031                  265                 2000            226               326             nd
  4 μg/ml GJ175031                  201                 1842            133               231             2.5/3.5
  0.8 μg/ml GJ175031                120                 473             77                132             0.5/3.2
  0.8 μg/ml GJ175031 + PK           3.1                 --1             --1               --3             3.5/3.5
  0.08 μg/ml GJ175031               9                   25              15                9               3.0/3.2
  Endogenous HGF from blood donor   209                 172             218               221             0.9/3.3
  RHGF QF031062 2 -- 100 ng/ml      12                  6               −5                −3              3.4/3.5

The immobilisation levels for ligands are given in parentheses. The same chip was used for all measurements. Biologically active endogenous HGF was used as a positive control. The rHGF GJ175031 + PK as well as the biologically inactive rHGF lot GJ1750031 ([@b20]) at different dilutions were used as negative controls. Because rHGF GJ175031 had binding affinity to all of the ligands in the study, this lot was termed "SPR responsive." The biological activity was determined by measurement of the nude area after addition of rHGF to injured CCL-53.1 cells. The motogen activity of biologically active HGF causes migration of nearby cells towards the injured area and a subsequent decrease in nude area size ([@b22]). The biologically inactive rHGF QF031062 had no affinity to the ligands at different concentrations and was therefore "SPR non-responsive."

Binding of HGF to HSPG/dextran sulphate (DS) proved to be important for the biological activity of HGF. The addition of DS or HSPG to the samples reduced the binding (i.e. decreased the response) of HGF to the ligands ([Figure 1](#fig1){ref-type="fig"}), as well as decreased the biological activity of HGF. This observation is similar to the results obtained from analysis of HGF in the faeces of patients with acute infectious gastroenteritis ([@b19]), in which the binding signal to HGF ligands in SPR decreased significantly after the addition of DS to the samples. The decrease in binding signal might imply that the dextran-binding site of HGF overlaps with the antibody-binding epitope, or that dextran binding induces a conformational change in the HGF molecule.

In common with many other growth factors (e.g. the fibro blast growth factor family and vascular endothelial growth factor), HGF displays a strong affinity for heparin, and this proved to be a useful aid in its purification ([@b12]). Heparan sulphate (HS) is widely expressed, in the form of various proteoglycan species, on the surfaces of most cells and is secreted directly into the extracellular matrix ([@b12]). [@b8] demonstrated by affinity chromatography that HGF interacted with HSPG under physiological conditions of pH and ionic strength. This interaction appeared to be mediated solely by the HS chains and was of comparable affinity to the interaction of HGF with heparin. In addition, heparin competitively inhibited the binding of HGF to HSPG. These results indicate that the primary HS-binding site, and perhaps also the heparin-binding site, is present on the α-chain of HGF ([@b3]). The HGF-binding site is present within the iduronate- and sulphate-rich domains of HS, and its structure has been partially elucidated ([@b3]). The interaction of HSPG with HGF seems to be mediated primarily by the HS chains and not the protein core.

![Effect of the addition of 10% DS (10 mg/ml in MQ water) to an rHGF lot (diluted in PBS) on the SPR binding response to different HGF ligands.](ggrf26-163-f1){#fig1}

[Figure 1](#fig1){ref-type="fig"} shows that the binding of HGF to antibodies raised against the N-terminus of HGFβ (N19), the N-terminus of HGFα (N17), amino acids 32--176 of HGFα (H145), and an internal region of HGFβ (D19) might correlate with the dextran-binding affinity of HGF. The present work does not address the mechanism of the difference between biologically active and inactive HGF with regard to the binding affinity to these epitopes. However, previous studies have highlighted the role of HGFβ in the biological activity of HGF. [@b25] showed that the HGF β-chain alone binds c-Met and reported the crystal structure of HGFβ in complex with the Sema and PSI domains of the c-Met receptor. The c-Met Sema domain folds into a seven-bladed β-propeller in which the bottom faces of blades 2 and 3 bind to the HGF β chain "active site region". Mutation of HGF residues in the area that corresponds with the active site region in related serine proteases significantly impaired HGFβ binding to c-Met. [@b7] reported that an HGF variant with mutations at residues Y673 and V692, which are located in the active site region of the HGF β-chain, had binding affinity for c-Met in the context of two-chain HGF but had significantly impaired biological activity. In a previous study, we showed that after the binding of HGF from conditioned medium of injured keratinocytes to the c-Met receptor, the affinity of HGF for the H-145 antibody ([Table I](#tbl1){ref-type="table"}) decreased, which might indicate that the H-145 epitope is involved in HGF interaction with the c-Met receptor ([@b21]). Further studies are planned to investigate the underlying mechanisms for these observations.

### Non-responsive lots

The lots of rHGF that showed no binding to any of the ligands or that bound MN ([Table I](#tbl1){ref-type="table"}) but displayed much lower binding of HSPG had no biological activity in the CCL-53.1 cell line ([@b22]) and were therefore regarded as biologically inactive ([Table II](#tbl2){ref-type="table"}). Binding of HGF to HSPG is important to facilitate the contact between HGF and its receptor ([@b6]; [@b24]). This factor might explain why the rHGF lots without affinity for HSPG and DS were biologically inactive.

Furthermore, the SPR non-responsive lots did not have the same affinities to antibodies developed against HGF peptides ([Table I](#tbl1){ref-type="table"}). In some lots there was a high affinity of HGF for MN (with unknown epitope, [Table I](#tbl1){ref-type="table"}) but a much lower affinity to other surfaces ([Figure 2](#fig2){ref-type="fig"}). In some lots there was no affinity to surfaces at all ([Table III](#tbl3){ref-type="table"}). As mentioned previously, the SPR responsive, biologically active lots showed a binding response to all surfaces. We have not studied the underlying mechanisms for such differences in ligand-binding profiles between SPR responsive and non-responsive lots. Further studies are planned to analyse the molecular basis of these differences.

### Time-related changes in binding

By repeated analysis of the binding responses of different HGF lots to surfaces with time, we observed that the freshly reconstituted rHGF lots from the same batch had a similar binding response to ligands. However, this binding response decreased within minutes after reconstitution. Thus, we analysed the binding response of one SPR responsive and one SPR non-responsive lot to ligands that might be important in distinguishing the biologically active lots. As shown in [Figure 2](#fig2){ref-type="fig"}, the non-responsive rHGF lot had an initially high affinity to MN but much lower affinity to D19 and HSPG. However, the binding response to MN decreased significantly over time. On the other hand, in a reconstituted SPR responsive rHGF lot, the binding of HGF to HSPG decreased as the first step in the process of inactivation ([Table IV](#tbl4){ref-type="table"}). In another experiment, the binding of carrier-free HGF was better preserved after 15 h at room temperature than after thawing a sample within 15h of freezing (--20°C) and reconstitution ([Table V](#tbl5){ref-type="table"}). Although these are preliminary observations, the results might indicate that several freeze-thaw cycles are not beneficial for the biological activity of rHGF lots.

![Degradation of protein with time in the same run. The diagram shows a simplified report of the Biacore run (SPR signal; RU) during 15 h in the same chip. rHGF carrier-free R&D (GJ1907011) was reconstituted in 2 ml PBS to a concentration of 2.5 μg/ml. The ratio of the binding response to HSPG/MN in this lot (rHGF carrier-free, R&D GJ1907011) was 14/1025 = 0.01; therefore, the lot was considered biologically inactive. Positive and negative controls were included in the study but are not shown.](ggrf26-163-f2){#fig2}

###### 

Binding affinity of biologically active rHGF to MN and HSPG during incubation at room temperature.

  GJ1750031                   MN (22500 RU)   HSPG (14500 RU)
  --------------------------- --------------- -----------------
  rHGF, 1-h incubation        309             105
  rHGF, 24-h incubation       372             10
  rHGF + DS, 1 h              123             25
  rHGF + DS, 24 h             186             −17
  rHGF + MN 1:20, 1 h         23              33
  rHGF + MN, 24 h             −0.3            −24
  rHGF original + HSPG 1:20   116             −30

Lyophilized rHGF (5 μg/ml) was reconstituted in PBS, pH 7.4, to 1ml (5000 ng/ml). 100 μl was added to one tube containing 900 μl PBS and to two other tubes containing 890 μl PBS and 10 μl DS or MN to reach the dilution of 1:10 (500 ng/ml). HSPG was added to 100 μl un-diluted rHGF (5000 ng/ml). The initial four samples were analyzed in one Biacore run. Dilution and running of the four samples took 1 h. The samples were kept at room temperature for 24 hand then re-analysed in the same chip. The immobilisation levels (RU) are given in parentheses.

###### 

Binding of recombinant HGF (R&D carrier-free GJ174034, diluted in PBS) to ligands, showing degradation over time.

  Samples containing HGF                   C-met (22377 RU)   MN (19820 RU)   HSPG (14337 RU)
  ---------------------------------------- ------------------ --------------- -----------------
  2.5 μg/ml freshly reconstituted          194                1260            95
  After 34 min + PK (10 μl)                1                  −1              −19
  2.5 μg/ml after 15 h room temperature    181                373             147
  2.5 μg/ml after 15 h, −20°C and thawed   94                 283             45
  Negative control PBS                     −10                −8              −24
  Positive control after 15 h              403                508             512

The results are obtained from Biacore runs performed on the same chip. The immobilisation levels (RU) are mentioned in parentheses.

### Assessment of quality

By using the SPR-based method, we observed differences between HGF lots in the relative ligand-binding responses that correlated significantly with their quality ([Figure 3](#fig3){ref-type="fig"}). Samples containing bacteria or chemical preparations, which are unsuitable for biological *in vitro* assays, could be evaluated for HGF quality by SPR. In some rHGF lots, the appropriate dilution of HGF to use in experiments could be determined by analyzing different concentrations of rHGF with the Biacore instrument and by choosing the concentration that gave the most similar binding to all ligands ([Table III](#tbl3){ref-type="table"}).

![The histogram corresponding to a Biacore sensorgram from three lots of HGF. The first and second sensorgrams (1--2)(SPR non-responsive) belong to HGF with no biological activity in the *in vitro* assay (CCL-53.1 cells). The last sensorgram (3) belongs to biologically active HGF, which bound to all ligands with approximately the same absolute RU values (SPR responsive). The pills are showing the regeneration injections.](ggrf26-163-f3){#fig3}

### Buffy coat

rHGF lots were quite unstable in the SPR based analysis of HGF. However, our previous studies that analysed HGF in several patient groups ([@b13], [@b15],[@b16]) and that investigated the stability of HGF in serum/plasma ([@b14]) showed that endogenous HGF is fairly stable. The exact source of blood-borne HGF is unclear, but because HGF is present in many tissues, the tissues could contribute to plasma HGF in an endocrine manner. Another potential source of HGF in the blood is leukocytes, which contain substantial amounts of immuno reactive HGF ([@b28]; [@b2]).

We questioned whether chemical stress on the relatively stable endogenous HGF in blood might influence its binding affinity to the ligands that were important in distinguishing biologically active HGF. The buffy coat of peripheral blood is readily available from blood banks and contains a variety of white blood cells ([@b27]). Whole blood was gathered from a healthy volunteer, and the buffy coat was separated. The concentration (ELISA) and binding profile of HGF in the supernatant of buffy coat and in the serum of the same blood donor were analysed and shown to be similar ([Table V](#tbl5){ref-type="table"}). This result might indicate that serum is a reliable source for analysis of endogenous HGF. The pellet that contained the cells was placed at −70°C and then thawed to induce haemolysis. The concentration of HGF determined by ELISA in the haemolysed sample was higher than that in the non-haemolysed buffy coat, but the SPR response for all ligands in Biacore had decreased by, ≈50% ([Table VI](#tbl6){ref-type="table"}). This finding might indicate degradation of HGF by enzymes released after leukocyte lysis, which resulted in a high amount of biologically inactive HGF. Thus, SPR might be a more accurate indicator of protein quality than ELISA.

###### 

Analysis of HGF in buffy coat of blood donor by SPR (RU) and ELISA (ng/ml).

                                                                                                         HSPG   c-Met   N-17   D19   ELISA (dilution 1:10)
  ------------------------------------------------------------------------------------------------------ ------ ------- ------ ----- -----------------------
  Buffy coat centrifuged 3000g for 20 min, diluted 1:20 in PBS                                           35     247     272    335   3.7
  Serum from same person, diluted 1:20 in PBS                                                            38     317     336    330   2.3
  Haemolysed buffy coat, frozen at -70°C, thawed, centrifuged at 3000g for 20 min, diluted in 1:20 PBS   15     163     99     118   5.7

Statistical analysis of results could not be performed because there were too few observations.

Patients
--------

The HGF binding profile in patients with chronic leg ulcers was examined. We had observed previously that these patients had high amounts of endogenous HGF in ulcer secretions but decreased biological activity of HGF (from the same sample) in the CCL-53.1 cell line ([@b18], [@b22]). There was no significant correlation between age or sex of patients and healthy controls and the SPR response of HGF to the ligands. The binding response of HGF in plasma and in the ulcer secretions of patients with chronic leg ulcers differed significantly from that of healthy controls ([Table VII](#tbl7){ref-type="table"}). Binding to ligands crucial for the biological activity of HGF (e.g. HSPG, N17 and N19) was decreased in the plasma from patients with chronic ulcers compared with the plasma from healthy controls. However, direct biological activity of HGF was not observed upon adding whole blood, serum, or plasma to CCL-53.1 cells.

The ratio of the binding response of HSPG/MN in leg ulcer secretions correlated significantly with the biological activity of HGF ([Figure 4](#fig4){ref-type="fig"}). Therefore, patients with chronic leg ulcers exhibited a change in the quality of HGF in the blood and decreased biological activity of HGF in ulcer secretions. However, the mechanism behind the changed quality of HGF in the blood of patients with chronic leg ulcers is unclear. In some other chronic inflammatory diseases such as lung fibrosis, increased levels but decreased biological activity of HGF have been reported ([@b29]; [@b10]). Further studies are planned to investigate the mechanisms in patients with chronic leg ulcers.

![Concentration (detected by ELISA), biological activity (assessed in CCL-53.1 cells), and binding response to ligands (analysed by SPR) of HGF in ulcer secretions of patients with acute or chronic ulcers. The data on HGF concentration and biological activity were reported previously ([@b18]). The biological activity was determined by measurement of the nude area after addition of rHGF to injured CCL-53.1 cells. The motogen activity of biologically active HGF causes migration of nearby cells towards the injured area and a subsequent decrease in nude area size ([@b22]). In the present study, the ulcer secretions of the same patients and the same material were analysed by SPR. There was a significant negative correlation (*r* = 0.70, *r*^2^ = 0.49, *p* = 0.003) between the SPR binding response to ligands (HSPG/MN ratio) and the size of the nude area in injured CCL-53.1 cells.](ggrf26-163-f4){#fig4}

###### 

Statistical analysis of SPR ligand-binding response (RU) of endogenous HGF in plasma of patients with chronic leg ulcers (*n* = 16) compared with healthy controls (*n* = 20).

  Ligands   Median chronic ulcers   Median control   *p* value
  --------- ----------------------- ---------------- -----------
  N-17      173                     232              0.005\*
  HSPG      216                     450              0.010\*
  HSPG      217                     449              0.011\*
  N-19      220                     446              0.014\*
  HSPG      222                     444              0.017\*
  HSPG      224                     442              0.021\*
  H-145     232                     434              0.042\*
  H-170     245                     421              0.10
  C-20      251                     415              0.15
  PK        276                     389              0.53
  MN        279                     386              0.60
  c-Met     281                     385              0.64

The ligands ([Table I](#tbl1){ref-type="table"}) were immobilised on four Biacore chips, and HSPG was included in all four chips. The *p* values (\* = significant) indicate that the binding affinity of HGF to HSPG, N-17, N-19, and H-145 differed significantly between groups.

Conclusion
==========

SPR-based assessments of the binding profile of HGF to relevant ligands might rapidly and sensitively distinguish HGF variants with biological activity. Appropriate for clinical studies, this method might be used for evaluation of the quality of endogenous HGF and for recognition of patients who might benefitfrom exogenous HGF treatment.
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